Owkin vs PathAI
Detailed side-by-side comparison to help you choose the right tool
Owkin
Healthcare AI
Owkin is a full-stack AI biotech company using federated learning to train machine learning models on hospital data without centralizing patient records. Founded in 2016 and headquartered in Paris, Owkin has raised over $300M in funding, secured a strategic partnership with Sanofi valued at over $180M, and developed MSIntuit CRC—an FDA-cleared AI diagnostic for detecting microsatellite instability in colorectal cancer from standard pathology slides. The company operates the MOSAIC federated learning platform across 15+ academic medical centers worldwide and offers the K Pro AI Scientist for pharma decision-making across clinical trial, patient, and portfolio decisions.
Was this helpful?
Starting Price
CustomPathAI
🟢No CodeAutomation & Workflows
AI-powered digital pathology platform providing FDA-cleared diagnostic tools, biomarker analysis, and enterprise workflow management for laboratories and biopharma companies.
Was this helpful?
Starting Price
EnterpriseFeature Comparison
Scroll horizontally to compare details.
💡 Our Take
Choose Owkin if you want a broader platform that spans drug discovery, clinical trial optimization, and diagnostics, with federated learning across multiple hospital partners. Choose PathAI if your primary need is pure digital pathology workflows and companion diagnostic development, with deeper specialization in pathology lab integrations rather than pharma R&D decision-making.
Owkin - Pros & Cons
Pros
- ✓Unique federated learning architecture via MOSAIC enables training on real-world hospital data without centralizing patient records, providing access to more diverse and representative datasets than competitors
- ✓FDA 510(k)-cleared MSIntuit CRC diagnostic demonstrates regulatory validation, with the ability to triage approximately 30% of colorectal cancer cases without confirmatory molecular testing
- ✓Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration validate platform value for top-tier pharmaceutical companies
- ✓Over 80 peer-reviewed publications in journals like Nature Medicine and The Lancet Digital Health provide strong scientific credibility compared to many AI biotech peers
- ✓Founded in 2016 with over $300M raised and global presence across 7 offices (Paris, London, New York, Cambridge MA, Geneva, Nantes), giving institutional clients confidence in long-term viability
- ✓Multimodal approach combining pathology, genomics, spatial-omics and clinical data captures biological complexity beyond single-modality platforms
Cons
- ✗Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
- ✗Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
- ✗Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
- ✗No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
- ✗Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging
- ✗Regulatory approval for AI diagnostics varies by jurisdiction, and expanding beyond FDA-cleared products to additional cancer types and international markets involves lengthy timelines
PathAI - Pros & Cons
Pros
- ✓FDA 510(k) clearance for AISight Dx with PCCP enables regulatory-compliant AI diagnostics
- ✓Trained on 15M+ pathologist-verified annotations across multiple cancer types
- ✓Used by 90% of the top 15 biopharma companies for clinical trial pathology
- ✓Cloud-native architecture enables remote pathology consultation and collaboration
- ✓Integrated end-to-end offering from tissue processing through AI-powered diagnosis
- ✓Precision Pathology Network creates collaborative ecosystem for labs and pharma
Cons
- ✗Enterprise-only pricing excludes small independent pathology practices
- ✗Requires significant infrastructure investment for whole-slide image scanning and storage
- ✗Limited to anatomic pathology — does not cover clinical laboratory testing or radiology
- ✗Long implementation timelines typical of enterprise healthcare IT deployments
Not sure which to pick?
🎯 Take our quiz →🔒 Security & Compliance Comparison
Scroll horizontally to compare details.
Price Drop Alerts
Get notified when AI tools lower their prices
Get weekly AI agent tool insights
Comparisons, new tool launches, and expert recommendations delivered to your inbox.